JP4820518B2 - モルホリノ置換化合物治療薬 - Google Patents

モルホリノ置換化合物治療薬 Download PDF

Info

Publication number
JP4820518B2
JP4820518B2 JP2001553268A JP2001553268A JP4820518B2 JP 4820518 B2 JP4820518 B2 JP 4820518B2 JP 2001553268 A JP2001553268 A JP 2001553268A JP 2001553268 A JP2001553268 A JP 2001553268A JP 4820518 B2 JP4820518 B2 JP 4820518B2
Authority
JP
Japan
Prior art keywords
aryl
chr
substituted
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001553268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530318A (ja
JP2003530318A5 (enExample
Inventor
ロバートソン，アラン，ディー．
ジャクソン，シャウン
ケンチェ，ヴィジャヤ
ヤイプ，シンディー
パーバハラン，ヒシャニ
トンプソン，フィル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2003530318A publication Critical patent/JP2003530318A/ja
Publication of JP2003530318A5 publication Critical patent/JP2003530318A5/ja
Application granted granted Critical
Publication of JP4820518B2 publication Critical patent/JP4820518B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2001553268A 2000-01-24 2001-01-24 モルホリノ置換化合物治療薬 Expired - Fee Related JP4820518B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17735100P 2000-01-24 2000-01-24
US60/177,351 2000-01-24
US22582600P 2000-08-17 2000-08-17
US60/225,826 2000-08-17
PCT/IB2001/000079 WO2001053266A1 (en) 2000-01-24 2001-01-24 Therapeutic morpholino-substituted compounds

Publications (3)

Publication Number Publication Date
JP2003530318A JP2003530318A (ja) 2003-10-14
JP2003530318A5 JP2003530318A5 (enExample) 2007-12-06
JP4820518B2 true JP4820518B2 (ja) 2011-11-24

Family

ID=26873182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001553268A Expired - Fee Related JP4820518B2 (ja) 2000-01-24 2001-01-24 モルホリノ置換化合物治療薬

Country Status (14)

Country Link
US (4) US6977255B2 (enExample)
EP (2) EP1257537B1 (enExample)
JP (1) JP4820518B2 (enExample)
CN (3) CN1263743C (enExample)
AT (2) ATE363471T1 (enExample)
AU (2) AU3042601A (enExample)
CA (1) CA2398163C (enExample)
CY (1) CY1108023T1 (enExample)
DE (1) DE60128655T2 (enExample)
DK (1) DK1257537T3 (enExample)
ES (1) ES2286093T3 (enExample)
NZ (1) NZ520300A (enExample)
PT (1) PT1257537E (enExample)
WO (1) WO2001053266A1 (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785363B1 (ko) 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB2405093B (en) * 2001-08-14 2005-07-06 Cancer Rec Tech Ltd DNA-PK inhibitors
TW589181B (en) * 2001-09-05 2004-06-01 Eisai Co Ltd Lymphocytic activation inhibitor and remedial agent for autoimmune disease
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
NZ538420A (en) * 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta
CN101260104A (zh) * 2002-08-16 2008-09-10 阿斯利康(瑞典)有限公司 抑制磷酸肌醇3-激酶β
AU2003265585B2 (en) 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
AU2003280188A1 (en) 2002-12-06 2004-06-30 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
JP2006522124A (ja) * 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
JP2006523237A (ja) * 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
EP1636212B1 (en) * 2003-06-05 2007-06-27 Warner-Lambert Company LLC Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents
CA2527934A1 (en) * 2003-06-05 2004-12-16 Warner-Lambert Company Llc Tetrazol benzofurancarboxamides with p13k activity as therapeutic agents
US20040259926A1 (en) * 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
AU2004265149A1 (en) 2003-08-13 2005-02-24 Kudos Pharmaceuticals Limited Aminopyrones and their use as ATM inhibitors
MXPA06002513A (es) * 2003-09-04 2006-06-20 Warner Lambert Co Benzo[b]tiofenos halo-sustituidos con actividad inhibidora de fosfoinositido-3-cinasas (pi3k) como agentes terapeuticos.
WO2005042519A1 (en) * 2003-10-31 2005-05-12 Warner-Lambert Company Llc Pyrimidines as inhibitors of phosphoinositide -3-kinases (pi3k)
JP2007519742A (ja) * 2004-01-26 2007-07-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼの阻害剤として有用な組成物
ES2873875T3 (es) 2004-05-13 2021-11-04 Icos Corp Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
CN1300163C (zh) * 2004-06-23 2007-02-14 南京大学 3－羟基色原酮糖苷及其制法和用途
JP2008513428A (ja) 2004-09-20 2008-05-01 クドス ファーマシューティカルズ リミテッド Ｄｎａ−ｐｋ阻害剤
US7642254B2 (en) 2005-02-09 2010-01-05 Kudos Pharmaceuticals Limited ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
WO2007127366A2 (en) 2006-04-25 2007-11-08 Targegen, Inc. Kinase inhibitors and methods of use thereof
DK2044026T3 (da) * 2006-06-22 2014-06-30 Prana Biotechnology Ltd Fremgangsmde til behandling af cerebral glioma tumor
WO2008102932A1 (en) * 2007-02-21 2008-08-28 Biobud Co., Ltd. Compositions for treating hyperproliferative vascular disorders and cancers
EP2157092A4 (en) 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
JP2010529031A (ja) * 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
WO2009008991A2 (en) * 2007-07-06 2009-01-15 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Dna-pkcs modulates energy regulation and brain function
JP2011510071A (ja) * 2008-01-25 2011-03-31 アストラゼネカ アクチボラグ 鏡像異性的に純粋な（−）２−［１−（７−メチル−２−（モルホリン−４−イル）−４−オキソ−４Ｈ−ピリド［１，２−ａ］ピリミジン−９−イル）エチルアミノ］安息香酸、医学的療法における該物質の使用、および該物質を含む薬学的組成物−０２６
JP2011518174A (ja) * 2008-04-18 2011-06-23 シェノゲン ファーマ グループ リミテッド エストロゲン受容体に関連する疾患を処置するための化合物及び方法
KR20110065536A (ko) 2008-09-29 2011-06-15 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 퀴나졸리논, 퀴놀론 및 관련 유사체
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CA2743642C (en) 2008-11-13 2017-09-19 Calistoga Pharmaceuticals, Inc. Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
LT2448939T (lt) 2009-07-02 2017-06-12 Sanofi 2,3-dihidro-1h-imidazo {1,2-a} pirimidin-5-ono dariniai, jų gamyba ir farmacinis panaudojimas
AR077628A1 (es) 2009-07-02 2011-09-14 Sanofi Aventis Derivados de 6-(morfolin-4-il)-pirimidin-4(3h)-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fosforilacion de akt(pkb)
SI2448940T1 (sl) 2009-07-02 2014-10-30 Sanofi Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba
HRP20140478T1 (hr) 2009-07-02 2014-07-04 Sanofi Novi derivati (6-okso-1,6-dihidropirimidin-2-il)amida, njihovo dobivanje, te farmaceutska upotreba kao inhibitora fosforilacije akt
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
IT1403156B1 (it) * 2010-12-01 2013-10-04 Università Degli Studi Di Torino Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
WO2012085244A1 (fr) 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
FR2969613B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
PL2658844T3 (pl) 2010-12-28 2017-04-28 Sanofi Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)
TW201335151A (zh) * 2012-01-26 2013-09-01 Daiichi Sankyo Co Ltd 具有骨形成促進作用之色酮衍生物
PL2812004T3 (pl) * 2012-02-10 2019-01-31 Ptc Therapeutics, Inc. Związki do leczenia rdzeniowego zaniku mięśni
EA029155B1 (ru) 2012-03-01 2018-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
MX358514B (es) 2012-03-23 2018-08-24 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
ITMI20120514A1 (it) * 2012-03-29 2013-09-30 Cnr Consiglio Naz Delle Ric Erche Agente terapeutico per il trattamento dei vasi sanguigni
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
EP3594215A1 (en) 2013-12-20 2020-01-15 Gilead Calistoga LLC Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors
NZ726360A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
CN107635999B (zh) * 2015-05-20 2020-09-25 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
KR102488323B1 (ko) 2015-12-10 2023-01-12 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
WO2017103931A1 (en) 2015-12-17 2017-06-22 Biokine Therapeutics Ltd. Small molecules against cancer
JP6941611B2 (ja) 2015-12-17 2021-09-29 バイオカイン セラピューティックス リミテッド ケモカイン活性および／または癌細胞成長を阻害するための小分子
EP3496724B8 (en) * 2016-08-12 2021-11-17 Madera Therapeutics, LLC Protein kinase regulators
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
US11760762B2 (en) 2017-01-27 2023-09-19 Signalrx Pharmaceuticals, Inc. Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
KR20200033249A (ko) 2017-06-05 2020-03-27 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
JP2020523365A (ja) 2017-06-14 2020-08-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを改変する方法
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
AU2019294478B2 (en) 2018-06-27 2023-03-23 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CN109748914B (zh) * 2018-12-29 2021-05-25 上海珂臻医药科技有限公司 吡啶并嘧啶类化合物及其应用
CN114096524B (zh) 2019-05-15 2025-03-04 阿龙拜欧有限公司 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
CN111533721B (zh) * 2020-05-15 2022-04-26 浙江大学 苯并吡喃酮或喹啉酮类化合物及其应用
US20240208964A1 (en) * 2020-06-03 2024-06-27 Pyridopyrimidines And Methods Of Their Use Pyridopyrimidines and methods of their use
JP2024508045A (ja) * 2021-02-01 2024-02-21 ゲオデ セラピューティクス インコーポレイテッド ホスホイノシチド３キナーゼベータ阻害剤ならびにそれらの組成物および方法
AU2022268900B2 (en) 2021-05-03 2024-12-19 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
KR20240014065A (ko) 2021-05-27 2024-01-31 페트라 파마 코포레이션 암의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
EP4412606A4 (en) * 2021-10-07 2025-09-24 Relay Therapeutics Inc PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
WO2025136936A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Agonists of trem2 activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS604170A (ja) * 1983-06-21 1985-01-10 Nippon Shinyaku Co Ltd キノロン誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH04502322A (ja) 1988-12-21 1992-04-23 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
JPH05509302A (ja) 1990-06-20 1993-12-22 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS604170A (ja) * 1983-06-21 1985-01-10 Nippon Shinyaku Co Ltd キノロン誘導体

Also Published As

Publication number Publication date
DK1257537T3 (da) 2007-10-01
CN1263743C (zh) 2006-07-12
JP2003530318A (ja) 2003-10-14
US20030216389A1 (en) 2003-11-20
DE60128655D1 (de) 2007-07-12
ATE551325T1 (de) 2012-04-15
CY1108023T1 (el) 2013-09-04
US7572791B2 (en) 2009-08-11
AU2001230426B2 (en) 2005-12-01
HK1051187A1 (en) 2003-07-25
EP1857443B1 (en) 2012-03-28
CA2398163A1 (en) 2001-07-26
AU2001230426C1 (en) 2006-06-22
EP1857443A3 (en) 2007-12-26
EP1257537B1 (en) 2007-05-30
US20080312233A1 (en) 2008-12-18
PT1257537E (pt) 2007-08-03
US20080206312A1 (en) 2008-08-28
EP1257537A4 (en) 2003-04-23
ATE363471T1 (de) 2007-06-15
ES2286093T3 (es) 2007-12-01
NZ520300A (en) 2004-05-28
CN1891699A (zh) 2007-01-10
WO2001053266A1 (en) 2001-07-26
DE60128655T2 (de) 2008-02-07
HK1115378A1 (en) 2008-11-28
EP1857443A2 (en) 2007-11-21
EP1257537A1 (en) 2002-11-20
US7405211B2 (en) 2008-07-29
AU3042601A (en) 2001-07-31
CN1891693A (zh) 2007-01-10
US20050085471A1 (en) 2005-04-21
US6977255B2 (en) 2005-12-20
CN1418195A (zh) 2003-05-14
CA2398163C (en) 2011-02-22

Similar Documents

Publication Publication Date Title
JP4820518B2 (ja) モルホリノ置換化合物治療薬
JP4646626B2 (ja) ホスホイノシチド３−キナーゼβの阻害
JP3234221B2 (ja) ベンゾピラノン、それらの製造方法、及びそれらの利用
US7026484B2 (en) Tricyclic androgen receptor modulator compounds and methods
JP2003508397A (ja) アンドロゲンレセプターモジュレーターとしての８−置換−６−トリフルオロメチル−９−ピリド［３，２−ｇ］キノリン化合物
CZ302792A3 (en) Intima atherosclerotic concretion inhibitor
JPS60149576A (ja) 坑炎症剤として有用な置換ヒドロキシ−２，３−ジヒドロベンゾフランおよびその類似体
US5646164A (en) α-methylene-γ-butyrolactones: new inhibitors of platelet aggregation
JP2025517407A (ja) 線維性疾患治療用アゾロ化合物
JP2001302669A (ja) 三環性フタラジノン誘導体
JP7516365B2 (ja) 新規化合物
HK1051187B (en) Therapeutic morpholino-substituted compounds
HK1115378B (en) Therapeutic morpholino-substituted compounds
AU2003260916B2 (en) Inhibition of phosphoinositide 3-kinase-beta
JPS5953470A (ja) イミダゾ−ル誘導体

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070704

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110830

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110905

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140909

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees